Evofem Q3 2026: $1.0M Quarterly Profit Masks Going-Concern Warning and Dec 1 Debt Wall
EVFM has more than doubled off its 52-week low of $0.001 on light trading volume (0.3× avg).
Summary
Evofem reported a $1.0 million Q3 2026 profit driven by non-cash fair-value gains, while warning that its $0.3 million of restricted cash cannot cover $44 million of debt maturing December 1, 2026 and that substantial doubt exists about its ability to continue as a going concern.
Key Events · Earnings and Guidance · EVFM
-
Q3 Profit Is Non-Cash Driven
Q3 2026 net income was $1.0 million versus a $1.6 million loss a year earlier, but included a $1.5 million gain on change in fair value of financial instruments and a $0.4 million loss on debt extinguishment. Nine-month net loss was $15.5 million.
-
Going-Concern Warning Reiterated
Management states liquidity resources are not sufficient to fund operating requirements for at least twelve months from the filing date, raising substantial doubt about the company's ability to continue as a going concern. Restricted cash stood at just $0.3 million as of September 30, 2026.
-
December 1, 2026 Debt Wall
Approximately $34.6 million of Adjuvant Notes and $9.7 million of Exchanged SSNs both mature December 1, 2026. The Adjuvant Fifth Amendment on October 9, 2026 extended that maturity but the company says existing liquidity is insufficient to satisfy the obligations.
-
Future Pak Default Still Unresolved
Alleged events of default under the Baker Bros. Purchase Agreement remain unwaived and uncured as of September 30, 2026. If all purchasers exercise the Section 5.7 option, the repurchase price would be $106.8 million.
Analysis · EVFM · Life Sciences
Evofem posted a $1.0 million net profit for Q3 2026, but the swing came largely from a $1.5 million non-cash gain on the fair value of financial instruments and a $0.4 million debt-extinguishment loss, not from operations — nine-month losses still total $15.5 million. The balance sheet is the real story: $0.3 million of restricted cash, a $78.8 million working capital deficit, and $34.6 million of Adjuvant Notes plus $9.7 million of Exchanged SSNs both due December 1, 2026. Management states plainly that liquidity is insufficient to fund operations for at least twelve months and that substantial doubt exists about the company's ability to continue as a going concern. Layered on top is the unresolved Future Pak default notice, which if enforced could require a repurchase price of up to $106.8 million, and unremediated material weaknesses in internal controls. Revenue is shrinking — nine-month product sales fell 23% to $8.2 million — so the company needs a financing, restructuring, or asset sale before December 1 to avoid default or worse.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 49.5% of the 210 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.54%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, EVFM was trading at $0.01 on OTC in the Life Sciences sector, with a market capitalization of approximately $821.7K. The 52-week trading range was $0.00 to $0.01. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.